Jyoti S. Mayadev, MD, Discusses Multidisciplinary Focuses for Locally Advanced Cervical Cancer Following the CALLA Trial


Following the results of the phase 3 CALLA trial, Jyoti S. Mayadev, MD, discusses the importance of global clinical multidisciplinary efforts in the locally advanced cervical cancer space.

During the 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting, Jyoti Mayadev, MD, spoke with CancerNetwork® about where future multidisciplinary research efforts could be focused for patients with high-risk locally advanced cervical cancer following the phase 3 CALLA trial (NCT03830866).

Mayadev, a radiation oncologist and professor of radiation medicine and applied sciences at the University of California, San Diego School of Medicine, spoke about how clinical pathological factors such as lymph node status need to be better defined to further improve precision medicine options and better select patients for trial enrollment within this population.


Locally advanced cervical cancer still remains on our top-priority list in terms of improving [patient] outcomes. Even though the durvalumab [Imfinzi]/chemoradiation [in the] CALLA study did not meet its primary end point of progression-free survival, we see in the curves that we still have about 20% to 30% long-term in terms of improving cure and survival for these patients. Over time, we want to better select patients for these trials. Perhaps clinical pathological factors that we look at now such as lymph node positivity need to be further and better defined and refined in terms of personalized medicine. Who is really high-risk, and who could potentially relapse or recur after chemoradiation? [Those] are the patients that we really want to include in clinical trials and try to improve upon their outcomes.

The CALLA trial demonstrated and illustrated that across the globe, patients can be treated on a clinical trial with strong multidisciplinary collaboration in various pockets of the world. CALLA was truly a global clinical trial, and that’s the face of cervical cancer; 45% of our patients on CALLA were Hispanic/Latino and 40% were Asian. We can come together as a scientific community and produce better outcomes for patients through clinical trial development.


Mayadev JS, Rong, Y, Toita T, et al. Durvalumab in combination with chemoradiotherapy (CRT) in locally advanced cervical cancer (LACC): radiotherapy (RT) delivery and subgroup analyses from CALLA. Presented at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting; October 23-26, 2022; San Antonio, TX; LBA 03. Accessed October 27, 2022.

Related Videos
The AACR Health Disparities Report highlights the changes needed to achieve health equity for patients with cancer.
Robert A. Winn, MD, gives insight into how institutions and community practices can improve access to cancer care.
Patients with KRAS G12C-mutated non–small cell lung cancer who have brain metastases or intolerability of intravenous infusion may be more suitable to receive a small molecule inhibitor compared with chemotherapy, says Sandip P. Patel, MD.
Treatment with sotorasib or adagrasib appears to be more tolerable among patients with KRAS G12C-mutated non–small cell lung cancer compared with docetaxel, according to Sandip Patel, MD.
Notions of blame around smoking may be a prominent factor in patients with lung cancer feeling stigmatized for developing their disease, according to Lisa Carter-Bawa PhD, MPH, APRN, ANP-C, FAAN.
Considering cystectomy in patients with bladder cancer may help with managing the shortage of Bacillus Calmette-Guerin, according to Joshua J. Meeks, MD, PhD, BS.
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Patients with locally advanced or metastatic urothelial cancer and visceral disease may particularly benefit from enfortumab vedotin plus pembrolizumab, according to Amanda Nizam, MD.
High-grade adverse effects with zanidatamab plus palbociclib and fulvestrant seem to be uncommon in patients with HER2-positive, hormone receptor–positive, metastatic breast cancer, according to Sara Hurvitz, MD, FACP.
Treatment with toripalimab does not yield the same vascular toxicity seen with pembrolizumab in patients with advanced or metastatic nasopharyngeal carcinoma, according to Barbara Burtness, MD.
Related Content